Call Now

Rat VEGFC / VEGF-C Protein (aa 108-223, His Tag)

VEGFC

Catalog Number P80103-R08H
Organism Species Rat
Host Human Cells
Synonyms VEGFC
Molecular Weight The recombinant rat VEGFC comprises 127 amino acids and predicts a molecular mass of 14.5 kDa.
predicted N Ala 108
SDS-PAGE
Purity > 95 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the rat VEGFC (O35757) (Ala108-Arg223) was expressed, fused with a polyhistidine tag at the C-terminus.
Bio-activity 1. Immobilized rat VEGFC-His at 10 μg/mL (100 μL/well) can bind mouse VEGFR3-Fc (cat:50584-M02H), The EC50 of mouse VEGFR3-Fc (cat:50584-M02H) is 17.4-40.6 ng/mL.
2. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 30-150ng/mL.
Research Area Cancer |Signal transduction |Growth Factor & Receptor |Vascular Endothelial Growth Factor (VEGF) & Receptor |Vascular Endothelial Growth Factor (VEGF)
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Vascular endothelial growth factor C (VEGF-C) is a member of the VEGF family. Upon biosynthesis, VEGF-C protein is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF-C protein is a dimeric glycoprotein, as a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. VEGF-C may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis. VEGF-C protein is over-expressed in various human cancers including breast cancer and prostate cancer. VEGF-C/VEGFR-3 axis, through different signaling pathways, plays a critical role in cancer progression by regulating different cellular functions, such as invasion, proliferation, and resistance to chemotherapy. Thus, targeting the VEGF-C/VEGFR-3 axis may be therapeutically significant for certain types of tumors.
Reference
  • Joukov V, et al. (1997) Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. 173(2): 211-5.
  • Su JL, et al. (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96(4): 541-5.
  • Anisimov A, et al. (2009) Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 104(11): 1302-12.